Xagenic Inc., a Toronto, Canada-based molecular diagnostics company developing a new technology for decentralized, rapid diagnostic testing and a true point-of-care platform. Our aim is to enable on-demand, near patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of first consultation. This will dramatically improve patient care and reduce health care costs. Xagenic has adapted this technology to permit rapid, enzyme-free detection of nucleic acids from clinical samples.
We are commercializing a simple and fully automated technology platform that will enable widespread decentralized diagnostic testing to be performed outside of clinical laboratories. Our team is developing infectious disease tests that will allow the detection of a variety of analytes in situations where rapid test turnaround will provide clinically actionable results.
Funding Rounds (4) - $47.3MUpdate
Current Team (4)Update
Board Members and Advisors (2)Update
|Jul 10, 2015||FinSMEs - FinSMEs|
|Jul 10, 2015||PE HUB - Xagenic scores Series B funds|
|Jul 9, 2015||Venture Capital News - Venture Capital Access Online|
|Jan 15, 2015||Fierce Biotech - Canadian VC CTI unveils a $112M new biotech fund|
|Oct 16, 2014||Business Wire India - Xagenic Appoints Timothy I. Still as President & Chief Executive Officer|
|Oct 15, 2014||Business Wire - Xagenic Announces $6 Million Genome Canada Funded Project in Partnership with University of Toronto|
|Jul 14, 2014||Digital Journal - Xagenic Announces Second Closing of $25.5M Series B Financing|
|Jul 14, 2014||FinSMEs - Xagenic Raises Additional $5.5m in Series B Financing|
55 York Street
Toronto, ON M5J 1R7